Protein Alternatives SL (PROALT) received the Prize as the BEST BIOTECHNOLOGICAL STARTUP in the first edition of the #startups #awards of LA RAZON. The event was chaired by the Mayor of Madrid José Luis Martínez-Almeida, who was accompanied by Andrés Navarro, CEO of LA RAZÓN and the director Francisco Marhuenda. This first edition of the Sartup Awards has [...]
September 14th, 2021 ProAlt will be present at BioSpain 2021 from the 29th September to the 1st October and will participate in the one-to-one meetings to present to investors and pharma companies the latest results of its anti-cadherins_RGD therapeutic antibodies in oncology. BioSpain is the 10th International Trade Show & Partnering Event that will take [...]
September 6th, 2021 Protein Alternatives (ProAlt) was selected by the European Innovation Council Business Acceleration Services to present to Merck its therapeutic antibody PA-0661 in oncology. ProAlt will be one of the 16 selected companies from 10 different countries that will present innovative projects to Merck on September 30. Merck, the multinational Healthcare, Life Science [...]
April 12th, 2021 The XX Pharma-Biotech Cooperation Meeting will be a digital event organized by FarmaIndustria in April 28, 2021 where selected projects from the Spanish National Research Council (CSIC) and its spin-offs will be presented to pharmaceutical companies. PROALT was selected to present its most advanced therapeutic product PA-0661, a monoclonal antibody for the [...]
April 9th, 2021. PROALT has received the Innovative SME Seal, valid until April 2024. Innovation is one of the key factors for the economic and social development of any country. Through the Innovative SME Seal, the Ministry of Science and Innovation recognizes companies that carry out activities in the field of research, technological development and [...]
January 14th, 2021 Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of therapeutic monoclonal antibodies in oncology, has been selected as one of the two companies that will receive funding from the R&D and innovation programme of Madrid Region during 2021 and 2022. MetastCure project, with title “Preclinical evaluation of [...]
December 1st, 2020 Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of diagnostic and therapeutic products in oncology and research services provider, announces today the opening of its new office in Boston at the Cambridge Innovation Center (CIC). United States is one of the priority markets for the organization and [...]
October 26th, 2020 BIO-Europe is the largest partnering conference in Europe dedicated to the global biotechnology industry. On this occasion, it will be held in digital format from October 26 to 29. The conference brings together delegates from the entire value chain of the biotech industry, who come to event to identify, negotiate and start [...]
September 28th, 2020 AseBio Investor Day 2020 is a digital event from September 28th to October 1st, organized by the Spanish Association of Bioempresas (AseBio), together with the Biotechnology Market Platform (Ministry of Science), Innovation and Universities, the Institute of Foreign Trade (ICEX) and the BioVoices project. PROALT will participate in the partnering event and [...]
1st, October 2018 From September 25 to 27, the meeting organized by ASEBIO and the Junta de Andalucía brought together in Seville the largest national and international agents in the biotechnology sector. PROALT has participated in the partnering event and met during these days with investors, customers and potential commercial and technological partners. The company [...]
Copyright ©2020 Protein Alternatives SL. All rights reserved | Legal Notice & Privacy Policy
